<DOC>
	<DOCNO>NCT02714283</DOCNO>
	<brief_summary>The purpose study provide patient physician great understand risk benefit commonly use therapy treatment non-CF bronchiectasis</brief_summary>
	<brief_title>Comparative Effectiveness Safety Inhaled Corticosteroids Antimicrobial Compounds Non-CF Bronchiectasis</brief_title>
	<detailed_description>Non-CF bronchiectasis chronic inflammatory lung disease closely link pulmonary NTM disease . Both rare rise incidence disproportionately affect elderly woman . Therapy non-CF bronchiectasis aim reduce inflammation via either ICS-induced immunosuppression antibiotic-associated immunomodulation and/or suppression pathogenic organism . Both strategy , pursue long-term alone case concomitantly , inherent risk , relative risk benefit differential approach poorly study date . Ultimately , study provide patient physician great understand risk benefit therapeutic choice .</detailed_description>
	<mesh_term>Bronchiectasis</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<mesh_term>Erythromycin</mesh_term>
	<criteria>Within Medicare data , indicate diagnosis Bronchiectasis Pulmonologist ( ICD9 code 494.0 and/or 494.1 ) cystic fibrosis diagnosis , HIV infection , history organ transplant</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>nontuberculous mycobacteria</keyword>
	<keyword>corticosteroid</keyword>
	<keyword>macrolides</keyword>
	<keyword>antibiotic</keyword>
</DOC>